Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm AZD2811 + Durvalumab in relapsed small cell lung cancer (SUKSES-N5)
KCT0005379Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Sep 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of defosbarasertib and durvalumab in small cell lung cancer (SCLC), sponsored by AstraZeneca. Started Sep 2020; status: terminated.
02
Drugs
defosbarasertibdurvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on KCT0005379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005379.